Analyst Stacy Ku of TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Stacy Ku has given her Buy rating due to a combination of factors, primarily focusing on the promising sales trajectory and market potential of Aurinia Pharmaceuticals’ key product, Lupkynis. The third-quarter sales of Lupkynis exceeded expectations, reaching approximately $70.6 million, which was above the consensus estimate. This strong performance has led management to increase their 2025 sales guidance, reflecting confidence in continued growth despite a reduced sales force.
Additionally, the positive feedback from key opinion leaders (KOLs) suggests that Lupkynis will see steady adoption as healthcare providers gain more experience with the drug. The updated guidelines from the American College of Rheumatology (ACR) are also expected to support its use in first-line settings, enhancing its role in the treatment of lupus nephritis. Although there is some disappointment regarding Aurinia’s decision to remain independent, the long-term potential of Lupkynis and its expected market penetration reinforce the Buy rating.
In another report released on November 1, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $15.00 price target.